EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities
The current standard of care for patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions…